Aridis Pharmaceuticals Inc (ARDS)

Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on targeted immunotherapy for serious infectious diseases. The company develops fully human monoclonal antibody programs designed to address life-threatening infections, with AR-301 as its lead candidate. AR-301 has completed Phase III pivotal trials for lung infections caused by S. aureus alpha toxin and is also being studied as an adjunct to standard-of-care antibiotics for hospital-acquired pneumonia and ventilator-associated pneumonia.

Aridis is also advancing AR-320 for infections linked to methicillin-resistant and methicillin-susceptible Staphylococcus aureus, AR-501 for chronic lung infection associated with cystic fibrosis, and AR-101 for Pseudomonas aeruginosa targeting serotype O11. Its earlier-stage pipeline includes AR-401 for Acinetobacter baumannii, AR-201 for respiratory syncytial virus, and AR-701, a two-antibody cocktail. Founded in 2003, the company is headquartered in Los Gatos, California.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.